Structured around the development of a medical technology platform designed to enable rapid - and early-stage - detection of diseases, the Alamar Biosciences platform is designed and structured to develop antibody technologies for the diagnosis of various diseases to include cancer. The underlying concept is that earlier detection c/would enable pharma companies, medical practitioners and ultimately cancer patients to help detect -- and possibly achieve a cure - at a beginning stages.
